Additional file 8: Figure S6. of BET bromodomain inhibitors and agonists of the beta-2 adrenergic receptor identified in screens for compounds that inhibit DUX4 expression in FSHD muscle cells
Amy Campbell
Jonathan Oliva
Matthew Yates
Jun Zhong
Sean Shadle
Lauren Snider
Nikita Singh
Shannon Tai
Yosuke Hiramuki
Rabi Tawil
Silvère Maarel
Stephen Tapscott
Francis Sverdrup
10.6084/m9.figshare.c.3870838_D11.v1
https://springernature.figshare.com/articles/journal_contribution/Additional_file_8_Figure_S6_of_BET_bromodomain_inhibitors_and_agonists_of_the_beta-2_adrenergic_receptor_identified_in_screens_for_compounds_that_inhibit_DUX4_expression_in_FSHD_muscle_cells/5374558
Characterization of BET gene expression. (A-C) 54-2 FSHD1 and 54-6 control (non-FSHD, Normal) myoblasts were induced to differentiate into myotubes and gene expression measured. Differentiation efficiency was determined by examining the early differentiation marker MYOG and the late differentiation marker MYH2 (A). As expected, DUX4 targets were strongly induced upon differentiation of FSHD1 but not control myoblasts (B). The levels of BET family member (BRD2, BRD3, BRD4, BRDT) mRNAs are shown in (C). (D) Tracks showing ChIP-seq and RNA-seq reads mapped to the BRDT locus in DUX4-expressing muscle cells. Error bars indicate the standard deviation from the mean of three biological replicates. (PDF 117Â kb)
2017-09-04 05:00:00
Facioscapulohumeral muscular dystrophy
FSHD
DUX4
Bromodomain
Adrenergic
High-throughput screening